BridgeBio Pharma Inc.
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for CAH
Summary
On September 10, 2024, BridgeBio Pharma, Inc. reported topline results from its Phase 1/2 trial of BBP-631, an investigational gene therapy for Congenital Adrenal Hyperplasia (CAH). The study showed increased endogenous cortisol production in all patients at higher doses, and the therapy was well tolerated with no treatment-related serious adverse events. However, due to the data not warranting additional capital investment, BridgeBio plans to significantly reduce its gene therapy budget.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement